SGTX - Here's Why Sigilon Therapeutics Stock Is Tanking Today
Biotechnology start-up Sigilon Therapeutics (NASDAQ: SGTX) is getting beaten down after announcing a clinical hold for its experimental hemophilia drug. Investors worried testing might not resume hammered shares of the clinical-stage biotech stock 23.4% lower as of 12:55 p.m. EDT on Friday.
Last September, Sigilon Therapeutics began a clinical trial with its lead candidate, SIG-001. This complicated therapy is made of human cells engineered to express high levels of factor VIII (FVIII) for hemophilia A patients who can't produce their own.
Image source: Getty Images.
For further details see:
Here's Why Sigilon Therapeutics Stock Is Tanking Today